Incubated at Third Rock, Merida moves Fc therapies toward clinic with $121M: Finance Report

Immunology start-up Merida emerged from stealth mode this week with $121 million in series A cash to develop therapies that target pathogenic autoantibodies and the B cells that produce them.

The company originated as a project in the hands of Dario Gutierrez during a stint as an entrepreneur-in-residence at Third Rock Ventures. Gutierrez sought to create therapies that bind precisely to autoantibodies that cause diseases, adding an engineered Fc domain that clears them via the liver without an unwanted immune response...